Key result
Edoxaban was marginally superior to warfarin in reducing the risk of major adverse cardiac events in patients with atrial fibrillation (HR 0.90).
Why the study?
Warfarin has long been standard anticoagulant therapy for AF but is limited by drug interactions and monitoring, while edoxaban has shown favorable bleeding outcomes.
Does edoxaban improve cardiovascular and bleeding outcomes compared to warfarin in patients with atrial fibrillation?
Comparison
Edoxaban vs warfarin
Design
Systematic review and meta-analysis of randomized controlled trials
Authors
Loading...
Edoxaban reduces MACE and SSE versus warfarin in AF; confirms overall benefit but leaves open optimal use in high CHA₂DS₂-VASc or prior MI subgroups.
Meta-Analysis (n=26,832)
Does edoxaban improve cardiovascular and bleeding outcomes compared to warfarin in patients with atrial fibrillation?
Hazard Ratio: 0.9 (95% CI 0.83–0.97)
p-value: p=0.01
Edoxaban demonstrates robust efficacy in reducing MACE and stroke/systemic embolism in atrial fibrillation, though warfarin may remain preferable in specific high-risk subgroups such as those with high CHA₂DS₂-VASc scores or significant heart failure.
Sohail et al. (2025) conducted a meta-analysis in Atrial fibrillation (n=26,832). Edoxaban vs. Warfarin was evaluated on Major adverse cardiac events (MACE) (HR 0.90, 95% CI 0.83-0.97, p=0.01). Edoxaban was marginally superior to warfarin in reducing the risk of major adverse cardiac events in patients with atrial fibrillation (HR 0.90).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: